Europe Dry Eye Syndrome Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32
                     Europe Dry Eye Syndrome 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Accord ing  to  the  la t es t  repo r t  by  IMARC Group,  t i t l ed  "Europe Dry  Eye 
Syndrome Market :  Indust ry  T rends ,  Share ,  S i ze ,  Growth ,  Opportun i ty  and  
Forecast  2024-2032 ,"  t he  Europe  dry  eye  syndrom e marke t  s i ze  reached  US$  
757 .2  M i l l i on  in  2023.
Report Dry  eye  syndrome (DES) ,  a l so  known as  ke ra t ocon junc t i v i t i s  s i cca  (KCS) ,  i s  a  med ica l  cond i t i on  tha t  occu rs  due  to  t he  l ack  o f  mo is t u re  o r  lub r i ca t ion  on  the  
su r f ace  o f  t he  eye .  I t  i s  charac te r i zed  by  symptoms,  inc lud ing  i r r i t a t ion ,  redness ,  
Highlight and d ischarge ,  f a t igued  eyes ,  and  b lu r red  v i s i on .  
I t  i s  caused by  var ious  reasons  such  as  ho rmone changes ,  au to immune  d i sease ,  
Description i n f lamed eye l id  g lands ,  a l le rg i c  eye  d isease ,  ex tens ive  compu te r  usage,  and  med ica t ion  tha t  d i s rup t  t he  hea l t hy  tear  f i lm .  However ,  d ry  eye  syndrome can be  
t r ea ted  th rough  adm in i s t e r ing  a r t i f i c ia l  t ea rs ,  med i ca t i ons ,  l ac r ima l  p lugs ,  and  
su rge r ies .
Request  fo r  a  PDF sample  o f  th is  repor t :  
ht tps : / / www. imarcgroup .com/europe-d ry -eye -syndrom e-marke t / reques t sample
Report Description
Europe  Dry  Eye  Syndrome Market  T rends:
The  r i s ing  ger ia t r i c  popu la t i on ,  wh ich  i s  more  suscep t ib le  t o  ch ron ic  eye  d iseases ,  i s  one  o f  t he  key  fac t o r s  d r i v ing  
the  m arke t  g rowth .  D ry  eye  syndrome i s  a l so  caused  by  va r i ous  o ther  med ica l  cond i t i ons ,  such  as  S jogren ’s  
syndrome,  lupus ,  sc le roderma,  r heum at o id  a r t h r i t i s ,  sar co idos is ,  t hy ro id  d iso rders ,  and  d iabetes ,  wh ich  i s  h i gh ly  
p reva len t  among e lde r l y  pa t ien ts .  I n  add i t i on ,  seden ta ry  l i f es t y l es  and a  l ack  o f  phys ica l  ac t i v i t i es  o f  t he  masses  a re  
lead ing  to  inc reased  ox ida t i ve  s t ress  and reduced  muc in  exp ress ion  in  t he  eyes .  
As  a  resu l t ,  pa t i en ts  and hea l thca re  p rov ide rs  a re  w ide ly  adop t ing  cor t i cos te ro id  d rugs  to  e f f ec t i ve ly  t rea t  d ry  eye  
syndrome, .  Fur the rmore ,  t he  improv ing  d iagnos t i c  t echno log ies ,  r i s ing  hea l t hca re  expend i tu re  capac i t i es  o f  
consumers ,  and  inc reas ing  u t i l i za t ion  o f  smar t phones ,  l ap tops  and te lev i s ion  among  t he  m asses  lead ing  t o  p ro longed  
and excess ive  sc reen  t ime  a re  some o f  t he  o the r  f ac t o rs  c rea t ing  a  pos i t i ve  marke t  ou t l ook  ac ross  the  reg ion .
Look ing  fo rward ,  IMARC Group  expects  the  market  va lue  to  reach  US$  1 , 153 .5  Mi l l i on  by  2032,  exh ib i t ing  a  
CAGR o f  4 .6% dur i ng  the  fo recast  per iod  (2024-2032) .
V i ew Report  TOC,  F igures and  Tab les :  h t tps: / / www. i marcgroup .com/europe-dry -eye-syndrome-market
Breakup by Disease Type:
• Evaporative Dry Eye Syndrome
• Aqueous Dry Eye Syndrome
 
Breakup by Drug Type:
• Anti- infl ammatory Drugs
• Lubricant Eye Drops
Report 
• Autologous Serum Eye Drops
Segmentation
Breakup by Product:
• Liquid Drops
• Gel
• Liquid Wipes
• Eye Ointment
• Others
Breakup by Distribution Channel:
• Hospital  Pharmacies
• Retai l  Pharmacies
• Online Pharmacies
Breakup by Country:
Report 
• Germany
Segmentation • France
• United Kingdom
• I ta ly
• Spain
• Others
How has the Europe dry eye syndrome market 
performed so far and how will it perform in the 
coming years?
What has been the impact of COVID-19 on the 
Europe dry eye syndrome market?
Key What are the key regional markets?
Questions 
Answered in What is the breakup of the market based on the disease type?
the Report
What is the breakup of the market based on the 
drug type?
What is the breakup of the market based on the 
product?
What is the breakup of the market based on the 
distribution channel?
What are the various stages in the value chain of 
the industry?
What are the key driving factors and challenges in 
the industry?
Key 
What is the structure of the Europe dry eye 
Questions syndrome market and who are the key players?
Answered in 
What is the degree of competition in the industry?
the Report
What is the degree of competition in the industry?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
    4 . 1     O v e r v i e w
Contents     4 . 2     K e y  I n d u s t r y  T r e n d s5     E u r o p e  D r y  E y e  S y n d r o m e  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  D i s e a s e  T y p e
    6 . 1     E v a p o r a t i v e  D r y  E y e  S y n d r o m e  
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     A q u e o u s  D r y  E y e  S y n d r o m e
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  D r u g  T y p e
    7 . 1     A n t i - i n f l a m m a t o r y  D r u g s
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
       
    7 . 2     L u b r i c a n t  E y e  D r o p s
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     A u t o l o g o u s  S e r u m  E y e  D r o p s  
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  P r o d u c t
    8 . 1     L i q u i d  D r o p s  
        8 . 1 . 1  M a r k e t  T r e n d s
        8 . 1 . 2  M a r k e t  F o r e c a s t
    8 . 2     G e l  
Table of         8 . 2 . 1  M a r k e t  T r e n d s        8 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 3     L i q u i d  W i p e s  
        8 . 3 . 1  M a r k e t  T r e n d s
Contents         8 . 3 . 2  M a r k e t  F o r e c a s t    8 . 4     E y e  O i n t m e n t  
        8 . 4 . 1  M a r k e t  T r e n d s
        8 . 4 . 2  M a r k e t  F o r e c a s t
    8 . 5     O t h e r s
        8 . 5 . 1  M a r k e t  T r e n d s
        8 . 5 . 2  M a r k e t  F o r e c a s t
9    M a r k e t  B r e a k u p  b y  D i s t r i b u t i o n  C h a n n e l
    9 . 1     H o s p i t a l  P h a r m a c i e s
        9 . 1 . 1  M a r k e t  T r e n d s
        9 . 1 . 2  M a r k e t  F o r e c a s t
    9 . 2     R e t a i l  P h a r m a c i e s
        9 . 2 . 1  M a r k e t  T r e n d s
        9 . 2 . 2  M a r k e t  F o r e c a s t     
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /e uro p e -d ry -ey e - sy ndro m e-ma rke
t / t o c
Disclaimer
© 2023  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145 
E-MAIL: [email protected]